hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
== Illness and death == In June 2026, Chase was admitted to the Los Angeles General Medical Center for treatment of severe malnutrition following a period of extreme weight loss. During her hospitalization, her condition became increasingly critical after she was diagnosed with bacterial meningitis, several bloodstream infections, and AIDS. Doctors stated that she did not have much time left to live. To help manage rising medical expenses and support Chase in regaining stability, her alleged boyfriend, Roy Hernandez, created a GoFundMe crowdfunding campaign. In the campaign description, Hernandez said that Chase had faced significant personal difficulties in her post-acting life, including systemic bullying, a painful estrangement from her family, and ongoing housing instability in downtown Los Angeles. Chase died hours after the fundraising page was launched on June 16, from organ failure caused by her infections, substance abuse and AIDS. She was 35. A secondary cause of death was chronic polysubstance use. Hernandez publicly announced her death through TMZ the following day, June 17, stating that her bloodstream infections had led to septic complications that caused her body to shut down. Following her death, a dispute emerged regarding her final arrangements and the crowdfunding campaign, which Hernandez claimed was intended to help fund her cremation. Chase's former manager, John Ryan, and her father, John Schwallier, publicly denounced the fundraiser, advising fans not to donate.
On August 23, 2012, further results were published in the U.S. journal PLOS ONE in collaboration with Motoharu Seiki of the University of Tokyo Institute of Medical Science. By 2014, the technology had advanced to the stage of detecting Alzheimer’s-related substances directly from blood samples, and since April 2014, efforts under a new framework have been directed toward practical application.
==== Mechanism of action ==== One of the components in nabiximol, tetrahydrocannabinol (THC), weakly stimulates cannabinoid receptor 1(CBR1) and cannabinoid receptor 2 (CBR2) to produce analgesic effect (pain relief). Another component of nabiximol, cannabidiol (CBD), slightly inhibits the proliferation of T cells (a type of immune cells) and the activity of microglia (cells within the brain that regulate neural activity and repair).
Jain communities established large-scale systems for animal welfare long ago. Jain merchants funded the creation of panjrapoles—specialized animal shelters and hospitals across India designed to care for sick, old, or rescued livestock and birds. The motivation behind these early shelters was not modern ethical philosophy, but the core Jain religious belief that committing violence against any living creature directly harms a person's own soul and spiritual purity. Ethical vegetarianism has become popular in developed countries particularly because of the spread of factory farming and environmental consciousness. Some believe that the current mass-demand for meat cannot be satisfied without a mass-production system that disregards the welfare of animals, while others believe that practices like well-managed free-range farming or the consumption of game (particularly from species whose natural predators have been significantly eliminated) could substantially alleviate consumer demand for mass-produced meat.
==== Malabsorption ==== Individuals with pernicious anemia do not have the ability to produce intrinsic factor. Individuals who lack intrinsic factor have no ability to absorb vitamin B12. The lack of intrinsic factor is most commonly due to autoimmune gastritis, which causes an autoimmune attack on the parietal cells that create it in the stomach. Antacid drugs that neutralize stomach acid, as well as acid-suppressing agents such as proton-pump inhibitors, can inhibit the absorption of vitamin B12 by preventing its release from food in the stomach. Other causes of B12 malabsorption include bariatric surgery, pancreatic insufficiency, obstructive jaundice, tropical sprue, celiac disease, inherited intrinsic factor deficiency, and radiation enteritis affecting the distal ileum. Age is also a contributing factor: elderly individuals are often achlorhydric due to reduced parietal cell function in the stomach, increasing their risk of vitamin B12 deficiency. The ability to absorb vitamin B12 declines with age, particularly in individuals over 60.
Sources: en.wikipedia.org
== Treatment == Treatment for people with anorexia nervosa should be individualized and tailored to each person's medical, psychological, and nutritional circumstances. Treating this condition with an interdisciplinary team is suggested so that the different health care professional specialties can help addresses the different challenges that can be associated with recovery. Treatment for anorexia typically involves a combination of medical, psychological interventions such as therapy, and nutritional interventions (diet). Hospitalization may also be needed in some cases, and the person requires a comprehensive medical assessment to help direct the treatment options. There is no conclusive evidence that any particular treatment approach for anorexia nervosa works better than others. In some clinical settings a specific body image intervention is performed to reduce body dissatisfaction and body image disturbance. Although restoring the person's weight is the primary task at hand, optimal treatment also includes and monitors behavioral change in the individual as well. In general, treatment for anorexia nervosa aims to address three main areas:
December 13: Constitution of 22 Frimaire Year VIII (establishing the Consulate) grants citizenship only to men over 21, born and residing in France, and registered in their commune's civic registry, effectively excluding women. 1800
=== Privacy and fungibility === Bitcoin is pseudonymous, with funds linked to addresses, not real-world identities. While the owners of these addresses are not directly identified, all transactions are public on the blockchain. Patterns of use, like spending coins from multiple inputs, can hint at a common owner. Public data can sometimes be matched with known address owners. Bitcoin exchanges might also need to collect personal data as per legal requirements. For enhanced privacy, users can generate a new address for each transaction. In the bitcoin network, each bitcoin is treated equally, ensuring basic fungibility. However, users and applications can choose to differentiate between bitcoins. While wallets and software treat all bitcoins the same, each bitcoin's transaction history is recorded on the blockchain. This public record allows for chain analysis, where users can identify and potentially reject bitcoins from controversial sources. For example, in 2012, Mt. Gox froze accounts containing bitcoins identified as stolen.
Robert Thomas Dursley Stott. For services to the British Red Cross Society on the Isle of Man. June Street, Executive Manager, Dacorum Council for Voluntary Service. For services to the community. Richard Kenneth Swan. For services to Tourism. Geoffrey Trevor Theobald. For political and public service. David Geraint Price-Thomas, lately Under Secretary (Wales), Council of Welsh Districts. For services to Local Government in Wales. Joan Margaret Elizabeth Thompson, . For public service. Kenneth Trench, Chairman, Maxwell Pensioners' Action Group. For services to Pensions Legislation. Michael Victor Upson, , lately Grade 6, Foreign and Commonwealth Office. Derek Eustace Murray Walker, Director, Worldware. For services to Public Awareness of Aid Issues. Professor Herbert Wallace. For services to the community. Trevor Ward, lately Head of Aerodrome Standards Department, Civil Aviation Authority. For services to Aviation. Hugh Ingram Watson, , Commandant, Scottish Police College. Kathleen Watson, Business Requirements Analyst, Board of Inland Revenue. Michael Robert Clarkson Webb. For services to the community in Surrey. Anthony Barton Wells. For services to the Family Justice System. Patrick Whinney, , President, Guernsey Cheshire Home Foundation. For services to the community. Annarosa Whitehead. For services to the Women's Transport Service (First Aid Nursing Yeomanry). John Charles Williams, Secretary and Chief Executive, Institution of Electrical Engineers. For services to Electrical Engineering. William Gwyn Williams.
=== Breast changes === Spironolactone can cause breast pain and enlargement in women. This is "probably because of estrogenic effects on target tissue." At low doses, breast tenderness has been reported in only 5% of women, but at high doses, it has been reported in up to 40% of women. Breast enlargement and tenderness may occur in 26% of women at high doses. Some women regard spironolactone-induced breast enlargement as a positive effect. Spironolactone also commonly and dose-dependently produces gynecomastia (breast development) as a side effect in men. At low doses, the rate is only 5 to 10%, but at high doses, up to or exceeding 50% of men may develop gynecomastia. In the RALES, 9.1% of men taking 25 mg/day spironolactone developed gynecomastia, compared to 1.3% of controls. Conversely, in studies of healthy men given high-dose spironolactone, gynecomastia occurred in 3 of 10 (30%) at 100 mg/day, in 5 of 8 (62.5%) at 200 mg/day, and in 6 of 9 (66.7%) at 400 mg/day, relative to none of 12 controls. The severity of gynecomastia with spironolactone varies considerably, but is usually mild. As with breast enlargement caused by spironolactone in women, gynecomastia due to spironolactone in men is often, although inconsistently, accompanied by breast tenderness. In the RALES, only 1.7% of men developed breast pain, relative to 0.1% of controls. The time to onset of spironolactone-induced gynecomastia has been found to be 27 ± 20 months at low doses and 9 ± 12 months at high doses.
Sources: en.wikipedia.org
Plant foods lose less during processing, as they contain pyridoxine, which is more stable than the pyridoxal or pyridoxamine forms found in animal-sourced foods. For example, milk can lose 30–70% of its vitamin B6 content when dried. The vitamin is found in the germ and aleurone layer of grains, so there is more in grains from which these layers have not been removed, for example more in whole wheat bread than in white wheat bread, and more in brown rice than in white rice. Most values shown in the table are rounded to nearest tenth of a milligram:
== Toponym == The name of the town was attested in 1489, even before it was founded by François I in the form le Hable de Grace then Ville de Grace in 1516, two years before its official founding. The learned and transient name of Franciscopolis in tribute to the same king, is encountered in some documents then that of Havre Marat, referring to Jean-Paul Marat during the French Revolution but was not imposed. However it explains why the complementary determinant -de-Grace was not restored. This qualifier undoubtedly referred to the Chapel of Notre Dame located at the site of the cathedral of the same name. The chapel faced the Chapel Notre Dame de Grace of Honfleur across the estuary. The common noun havre meaning 'port' was out of use at the end of the 18th or beginning of the 19th centuries but is still preserved in the phrase havre de paix meaning 'safe haven'. It is generally considered a loan from Middle Dutch from the 12th century. A Germanic origin can explain the "aspiration" of the initial h. Havre de Grace, Maryland, in the United States retains the de Grace from colonial times. New research however focuses on the fact that the term was attested very early (12th century) and in Norman texts in the forms Hable, hafne, havene, havne, and haule makes a Dutch origin unlikely.
An advantage of the bacterial one-hybrid system over the yeast one-hybrid system (Y1H) lies in the higher transformation efficiency of plasmids into bacteria which allows for more complex “prey” libraries to be examined.
=== Films === The Devil We Know (2018): a documentary detailing the health dangers of PFAS. Dark Waters (2019): a thriller movie based on the corporate defense of PFAS and DuPont. Contaminated: The Carpet Industry's Toxic Legacy (2026): documentary about the history of PFAS and the carpet industry. Everywhere & Forever: Blood. Water. And the Politics of PFAS (2025): a documentary about PFAS and the struggles to manage the contamination. Revealed: How to Poison A Planet (2024): a documentary detailing the negative externalities from PFAS creation.
== Extraction == After finishing the digestion the peptides generated in this process have to be extracted from the gel matrix. This is accomplished by one or several extraction steps. The gel particles are incubated with an extraction solution and the supernatant is collected. In the first extraction, almost all of the peptide is recovered, the repetition of the extraction step can increase the yield of the whole process by only 5-10%. To meet the requirements of peptides with different physical and chemical properties an iterative extraction with basic or acidic solutions is performed. For the extraction of acidic peptides a solution similar to the concentration and composition of the digestion buffer is used; basic peptides are extracted in dependence to the intended mass spectrometric method with a low concentrated acidic solution of formic acid for ESI and trifluoroacetic acid for MALDI respectively. Studies on model proteins showed a recovery of approximately 70–80% of the expected peptide yield by extraction from the gel. Many protocols contain an additional fraction of acetonitrile to the extraction solution which, in concentrations above 30% (v/v), is effective in reducing the adsorption of peptides to the surface of reaction tubes and pipette tips. The liquid of the pooled extracts is evaporated in a centrifugal evaporator. If the volatile salt ammonium bicarbonate was used for the basic extraction, it is partially removed in the drying process. The dried peptides can be stored at -20 °C for at least six months.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.